STOCK TITAN

Kezar Life Sciences to Participate in the Jefferies Virtual Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Kezar Life Sciences, a clinical-stage biotechnology firm focusing on immune-mediated and oncologic disorders, announced that CEO John Fowler will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on June 3, 2021, at 2:00 p.m. ET. The chat will be accessible via live webcast on the company's website, with a replay available for 90 days post-event. Kezar is developing innovative therapies, including KZR-616 for lupus nephritis and KZR-261, targeting cancer treatment.

Positive
  • None.
Negative
  • None.

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced its Chief Executive Officer, John Fowler, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021 at 2:00 p.m. ET.

A live webcast of the fireside chat may be accessed at the “Events & Presentations” section of the Company’s website at http://investors.kezarlifesciences.com/events. Kezar Life Sciences will maintain an archived replay of the webcast on its website for 90 days after the conference.

About Kezar Life Sciences

Kezar Life Sciences is a clinical-stage biopharmaceutical company bringing novel treatments to patients with rare autoimmune diseases and cancer. The company is pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function to inhibit multiple drivers of disease via single, powerful targets. KZR-616, its lead development candidate, is a selective immunoproteasome inhibitor being evaluated in Phase 2 clinical trials in lupus nephritis, dermatomyositis and polymyositis. Additionally, KZR-261, the first anti-cancer clinical candidate from the company’s platform targeting the Sec61 translocon and the protein secretion pathway, is undergoing IND-enabling activities. For more information, visit www.kezarlifesciences.com.

FAQ

When is the Jefferies Virtual Healthcare Conference where KZR's CEO will speak?

The Jefferies Virtual Healthcare Conference will take place on June 3, 2021, at 2:00 p.m. ET.

How can I watch the fireside chat featuring KZR's CEO?

The fireside chat can be accessed live via webcast on the Events & Presentations section of Kezar Life Sciences' website.

What is KZR-616 and its significance?

KZR-616 is a selective immunoproteasome inhibitor being evaluated in Phase 2 clinical trials for lupus nephritis, among other conditions.

What other therapies is Kezar Life Sciences developing?

In addition to KZR-616, Kezar is developing KZR-261, an anti-cancer candidate targeting the Sec61 translocon.

Kezar Life Sciences, Inc.

NASDAQ:KZR

KZR Rankings

KZR Latest News

KZR Stock Data

54.36M
72.96M
14.8%
63.94%
1.64%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SOUTH SAN FRANCISCO